CION Ameerpet
Types & Staging · Reviewed by CION Oncologists · NABH Accredited
Endometrioid Adenocarcinoma — The Commonest Type
If this is the diagnosis on your report, the first thing worth knowing is that it is the one most women with endometrial cancer have — around eight in ten — and it is generally the most favourable. “Endometrioid” means the tumour still resembles the normal lining of the uterus. “Adenocarcinoma” simply means a cancer arising from gland tissue; it is a description of where it came from, not a statement about how serious it is. This type usually announces itself early through bleeding, is usually still confined to the uterus when found, and is usually very treatable. What determines your outlook is not the type name but the grade, the depth and the molecular class.
- The commonest type by far — around eight in ten cases
- “Adenocarcinoma” names the tissue — not the severity
- Usually caught early — because it causes bleeding
- Grade and molecular class matter more — than the type name itself
17+
Cancer Specialists
on Panel
on Panel
35+
Centres
Across India
Across India
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
What the Diagnosis Actually Means
Taking the words apart, because they are more descriptive than they sound.
- “Adenocarcinoma” describes the tissue of origin. Gland tissue. It appears in the names of cancers arising anywhere glands exist — bowel, lung, breast, prostate. It carries no implication of severity, and people frequently read it as though it did.
- “Endometrioid” means it still looks like uterine lining. The tumour has retained the appearance of the tissue it came from. That is a favourable feature, and it is what distinguishes this type from the more aggressive ones.
- It is usually oestrogen-driven. This is the type associated with the risk factors that run through this site — weight, cycles without ovulation, unopposed oestrogen. It frequently arises from a background of hyperplasia. See endometrial hyperplasia.
- It is often called Type 1. An older but still-used classification separating oestrogen-driven endometrioid cancers from the non-oestrogen-driven, more aggressive Type 2 tumours. See Type 1 endometrial cancer.
- Within the type, grade does the work. Grade 1 endometrioid and grade 3 endometrioid behave quite differently, so the type alone tells you relatively little. See grades explained.
Did You Know? Endometrial cancer has an advantage most cancers lack: it produces a symptom early, and that symptom is unmistakable after menopause. Bleeding when there should be none sends women to a doctor while the disease is still confined to the uterus, and endometrioid adenocarcinoma is the type that most reliably behaves this way. That is the principal reason a majority of endometrial cancers are diagnosed at an early stage, and why outcomes for this type are among the better ones in gynaecological oncology. It also explains why everything on this site keeps returning to the same message about bleeding — it is the mechanism by which the good outcomes happen. Sources: WHO Classification of Tumours — Female Genital Tumours; NCCN Clinical Practice Guidelines in Oncology — Uterine Neoplasms; ESGO–ESTRO–ESP guidelines for the management of patients with endometrial carcinoma.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
What Actually Determines Your Outlook
Five factors, weighed together. Any one read in isolation gives a distorted picture.
| Factor | Why it matters |
|---|---|
| Stage | How far the disease has spread. The single most important factor, and the reason early diagnosis matters so much. Most endometrioid cancers are stage I when found. See FIGO staging. |
| Grade | How closely the tumour still resembles normal lining. Grade 1 is the most favourable; grade 3 behaves more aggressively and prompts more intensive treatment. See grade 3 endometrial cancer. |
| Depth of invasion | How far into the muscle wall of the uterus the tumour has grown. Less than half the thickness is a materially better position than more than half, and it is one of the strongest predictors of whether treatment after surgery is recommended. |
| Lymphovascular space invasion | Whether tumour cells are seen inside small vessels near the tumour. Substantial LVSI raises the risk of node involvement and of recurrence, and frequently influences the radiotherapy decision. See your pathology report. |
| Molecular class | The newest factor and increasingly the decisive one. A POLE-mutated tumour behaves far better than its grade suggests and may need less treatment; a p53-abnormal one may need more. Now part of FIGO 2023 staging. See molecular classification. |
A grade 3 endometrioid tumour that turns out to be POLE-mutated is a genuinely different situation from the same tumour without that finding. This is why molecular classification is worth insisting on — it is the one test that can reduce the treatment you need as readily as increase it.
Want Your Report Gone Through Properly?
Type, grade, depth and molecular class explained — and what each of them changes.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
The Word Adenocarcinoma Names the Tissue
Not the severity. It appears in cancers of the bowel, lung and breast alike.
How It Is Treated
Surgery first for almost everyone, with what follows decided on the final pathology.
- Hysterectomy with removal of tubes and ovaries. The core operation, usually done by keyhole or robotic surgery with a hospital stay of one to two nights. It is both the treatment and the definitive staging procedure. See hysterectomy.
- Assessment of the lymph nodes. Increasingly by sentinel node mapping, which provides the same staging information as removing many nodes while substantially reducing the risk of leg lymphoedema. See sentinel node biopsy.
- A wait of two to three weeks for final pathology. Frustrating and necessary. The decision about treatment after surgery rests on the whole tumour rather than on the biopsy, and it is made once that information is available. See treatment after surgery.
- Then, for some women, radiotherapy. Often vault brachytherapy, which treats the top of the vagina directly and is well tolerated; pelvic radiation where the risk profile warrants it. Many women with low-risk disease need nothing at all. See vault brachytherapy.
- Chemotherapy for a minority. Where the disease is more advanced, high grade with adverse features, or p53-abnormal. Not routine for early low-grade disease. See chemotherapy.
For a carefully selected group — grade 1 disease that appears confined to the lining in a woman who wishes to conceive — progestin treatment with close surveillance can be considered instead of immediate surgery. See fertility-sparing eligibility.
Want a Second Opinion Before Treatment?
Slides re-read, molecular testing completed if missing, and your case taken to our tumour board. The opinion is free.
Questions Worth Asking
Five that produce a concrete answer rather than general reassurance.
"What grade is it, and what stage?"
The two numbers that drive everything else, and they are frequently confused with one another. Grade describes how the cells look; stage describes how far the disease has spread. Ask for both, and ask what the stage rests on — depth of invasion, node status, whether anything was found outside the uterus.
"Which molecular group is it?"
A one-word answer: POLE-ultramutated, mismatch repair deficient, p53-abnormal, or no specific molecular profile. If it has not been determined, ask whether it can be done on the stored tissue — since FIGO 2023 incorporates it into staging, a tumour without it has not been fully staged.
"Will I need treatment after surgery?"
Often the answer is genuinely not known until the final pathology returns, two to three weeks after the operation. What a good unit can tell you beforehand is the range of possibilities and what each would involve, so that the wait is informed rather than blank.
"Was my case discussed at a tumour board?"
The recommendation should come from surgeons, radiation oncologists, medical oncologists and pathologists together. A plan assembled by one specialty tends to reflect that specialty's tools. It is a fair question and the answer should be yes.
"What did the mismatch repair testing show?"
Relevant beyond your own treatment, because loss of a mismatch repair protein may indicate Lynch syndrome, with implications for your siblings and children. Ask what further testing is planned if it was abnormal. See Lynch syndrome.
Why the Commonest Type Still Deserves a Specialist
Because within it, the decisions about who needs treatment after surgery are genuinely finely balanced.
Tumour board for every diagnosis
MMR / MSI testing as standard
Sentinel node mapping where it fits
Slides reviewed, not just the summary line
Fertility taken seriously
Second opinions welcomed, not resented
Take The Next Step
Most Are Found Early
Because this type bleeds, and bleeding after menopause sends women to a doctor.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
Endometrioid Adenocarcinoma — Frequently Asked Questions
What is endometrioid adenocarcinoma?
It is the commonest type of endometrial cancer, accounting for around eight in ten cases. The name is descriptive rather than ominous: "adenocarcinoma" means a cancer arising from gland tissue, which appears in the names of cancers of the bowel, lung and breast as well, and says nothing about severity. "Endometrioid" means the tumour still resembles the normal lining of the uterus, which is a favourable feature and is what distinguishes it from the more aggressive types such as serous and clear cell carcinoma. It is typically oestrogen-driven and often arises from a background of endometrial hyperplasia.
Is this a good type to have?
Relatively, yes — it is generally the most favourable of the endometrial cancer types, and it is the one most often found early. That is because it reliably produces abnormal bleeding, and bleeding after menopause sends women to a doctor while the disease is still confined to the uterus. Most cases are stage I at diagnosis, where outcomes are good. That said, the type name alone tells you relatively little: a grade 1 endometrioid tumour and a grade 3 endometrioid tumour behave quite differently, and stage, depth of invasion and molecular class all matter as much as the type.
What determines whether I need treatment after surgery?
A combination of factors weighed together: the stage, the grade, how deeply the tumour invaded the muscle wall of the uterus, whether lymphovascular space invasion is present and how extensive it is, whether lymph nodes are involved, and the molecular classification. Many women with early, low-grade disease confined to the uterus need nothing further after their operation. Others are offered vault brachytherapy, pelvic radiation, or chemotherapy. The decision is made on the final pathology from the removed uterus, which takes two to three weeks, and it should be made following multidisciplinary discussion.
Why does molecular classification matter if I have the common type?
Because it changes decisions within this type, in both directions. A grade 3 endometrioid tumour that turns out to be POLE-ultramutated behaves far better than its grade suggests, and appropriately selected women can safely avoid radiotherapy or chemotherapy that grade alone would have prompted. Conversely a tumour with abnormal p53 may warrant intensification even where other features look reassuring. Mismatch repair testing additionally screens for Lynch syndrome, with implications for your relatives. Since FIGO 2023 incorporates molecular class into staging, a tumour that has not been classified has not been fully staged.
Can I keep my uterus if I want children?
It is possible for a carefully selected group, and it needs to be raised early rather than after a plan has been made. The criteria are strict: grade 1 endometrioid carcinoma that appears confined to the lining of the uterus without invasion into the muscle, confirmed by MRI, in a woman who wishes to conceive. Treatment is with progestins and requires committed, repeated surveillance biopsies to confirm the tumour has regressed. It is not suitable for everyone and it carries risks that must be discussed frankly. Hysterectomy is usually recommended once childbearing is complete.
Medical disclaimer: This page provides general information about endometrioid adenocarcinoma, reviewed by a CION oncologist. It is not a substitute for individual medical advice. Prognosis and treatment depend on stage, grade, depth of invasion, lymphovascular space invasion and molecular classification, which should be interpreted by your treating team in the context of your complete pathology.